|本期目录/Table of Contents|

[1]周将,肖姝婷,赵亮,等.非布司他治疗糖尿病肾病合并高尿酸血症的临床疗效和安全性[J].慢性病学杂志,2020,21(09):1299-1301.
　ZHOUJiang,XIAOShu-ting,ZHAOLiang,et al.Clinical efficacy and safety of febuxostat in the treatment of diabetic nephropathy with hyperuricemia[J].,2020,21(09):1299-1301.
点击复制

非布司他治疗糖尿病肾病合并高尿酸血症的临床疗效和安全性

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
21
期数:
2020年09期
页码:
1299-1301
栏目:
论　著
出版日期:
2020-09-28

文章信息/Info

Title:
Clinical efficacy and safety of febuxostat in the treatment of diabetic nephropathy with hyperuricemia
作者:
周将; 肖姝婷; 赵亮; 宁爱丽; 肖业; 蔡娟; 胡喆
湖南省益阳市中心医院老年老干科，湖南 益阳 413000
Author(s):
ZHOUJiang; XIAOShu-ting; ZHAOLiang; NINGAi-li; XIAOYe; CAIJuan; HUZhe
Departmentof Geriatrics,YiyangCentralHospital,Yiyang,Hunan413000,China Correspondingauthor:XIAOShu-ting,E-mail:253492609@qq.com
关键词:
非布司他; 别嘌醇; 糖尿病肾病; 高尿酸血症; 不良反应
Keywords:
Febuxostat;  Allopurinl;  Diabetic nephropathy;  Hyperuricemia;  Adverse reaction
分类号:
R587.1
DOI:
-
摘要:
目的 观察非布司他治疗糖尿病肾病（DN）合并高尿酸血症（HUA）的临床疗效和安全性。 方法 选取2017年8月至2018年8月湖南省益阳市中心医院收治的80例DN合并HUA患者作为研究对象，采 用随机数字表法分成两组，每组40例。对照组采用口服别嘌醇和碳酸氢钠治疗，观察组采用口服非布司他降尿酸 治疗，两组均治疗8周后分析临床效果，对肾功能影响及不良反应。结果 与对照组相比，观察组在治疗8周 后，总有效率升高，差异有统计学意义（P<0.05），血尿酸、血肌酐、尿素氮水平均显著下降，差异有统计 学意义（P<0.05），观察组的不良反应发生率（10.00%）低于对照组（32.50%），差异有统计学意义（P<0.05）。 结论 DN合并HUA患者，使用非布司他降尿酸治疗，能改善患者的血尿酸及肾功能指标，不良反应发生率 低，临床疗效较好。
Abstract:
Objective To observe the clinical efficacy and safety of febuxostat in the treatment of dia-betic nephropathy（DN）with hyperuricemia（HUA）. Methods Eighty DN and HUA patients ad-mitted to Yiyang Central Hospital from August2017 to August 2018 were selected as the research ob-jects and randomly divided into two groups, 40 patients in each group. The control group was treated with oral allopurinol and sodium bicarbonate, while the observation group was treated with oral febuxo-stat. After 8 weeks of treatment, the clinical effects, effects on renal function and adverse reactions of both groups were analyzed. Results Compared with the control group after 8 weeks of treatment, the total effective rate of the observation group was higher（P<0.05）, and the levels of uric acid, cre-atinine and urea nitrogen were significantly decreased（P<0.05）. The incidence of adverse reactions in the observation group（10.00%）was lower than that in the control group（32.50%）, and the difference was statistically significant（P<0.05）. Conclusion For patients with DN complicated with HUA, the use of febuxostat could improve the blood uric acid and renal function indexes of patients with low in-cidence of adverse reactions and good clinical efficacy.

参考文献/References:

[1] Cui LF, Meng LM, Wang GY, et al. Prevalence and risk factors of hyperuricemia: results of the Kailuan cohort study [J]. Modern Rheumatol, 2017,27(6):1066-1071. [2] 中华医学会风湿病学分会.2016中国痛风诊疗指南[J].浙江医学, 2017,39(21):1823-1832. [3] 万志红.非布司他治疗痛风及高尿酸血症的疗效及不良反应观察 [J].中国实用医药,2016,(1):112-113. [4] 孙明姝,母义明,赵家军,等.中国临床指南现状分析及《中国高 尿酸血症与痛风诊治指南(2018)》制定介绍[J].中华内分泌代谢 杂志,2019,35(3):181-184. [5] 张春林,王小翠,王慧,等.非布司他治疗2型糖尿病肾病合并高尿 酸血症的临床观察[J].中国药房,2018,29(4):501-505. [6] 周宇,柯甦捷,刘礼斌.血尿酸与糖尿病肾病[J].国际内分泌代谢 杂志,2016,36(3):202-205. [7] Hamburger M, Herbert SB. 2011 Recommendations for the Diagnosis and Management of Gout and Hyperuricemia [J]. Physic Sportsmed, 2011,39(4):98-123. [8] 钟成福,刘佳,刘旭阳,等.非布司他联合小剂量螺内酯治疗早期 糖尿病肾病伴高尿酸血症的疗效观察[J].中国医学装备,2014,11 (S2):424-425. [9] 中国医师协会肾脏内科医师分会.中国肾脏疾病高尿酸血症诊治的 实践指南(2017版)[J].中华医学杂志,2017,97(25):1927-1936. [10] 中国医师协会肾脏内科医师分会.中国肾脏疾病高尿酸血症诊治 的实践指南(2017版)[J].中华医学杂志,2017,97(25):1927-1936. [11] 刘丹,吴红艳.非布司他治疗2型糖尿病早期肾病合并无症状高尿 酸血症的疗效观察[J].安徽医药,2018,22(10):1968-1971. [12] 朱和同,李先维.非布司他联合别嘌醇治疗慢性肾脏病伴高尿酸 血症的疗效与安全性[J].中国医院用药评价与分析,2017,17(7): 892-894.

备注/Memo

备注/Memo:
作者简介：周将，硕士研究生，主治医师，研究方向：肾脏 病学 通信作者：肖姝婷，E-mail:253492609@qq.com
更新日期/Last Update: 2020-09-28